A dose-finding study of the safety and tolerability of intravenous reovirus (REOLYSIN®) (pelareorep) plus granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with standard of care chemoradiotherapy (CTRT) /adjuvant chemotherapy for Glioblastoma Multiforme (GBM)
Phase of Trial: Phase I
Latest Information Update: 12 Jan 2018
At a glance
- Drugs Granulocyte macrophage colony stimulating factor (Primary) ; Pelareorep (Primary) ; Temozolomide
- Indications Glioblastoma
- Focus Adverse reactions
- 09 Feb 2017 New trial record
- 08 Feb 2017 Status changed from not yet recruiting to recruiting.
- 08 Feb 2017 Planned initiation date changed to 1 Mar 2017.